IRISYS LLC announced its 3rd contract with TFF Pharma


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ irisys-llc-manufacture-inhalable-lung-medication-potential-treat-covid19
IRISYS LLC signs the third contract with TFF Pharma to produce medication to treat lung conditions, including COVID-19

IRISYS LLC, a pharmaceutical contract manufacturing and development organization (CDMO) announced its third contract for production and manufacturing in partnership with TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company located in Austin, TX. Most recently, TFF Pharmaceuticals contracted with IRISYS to manufacture an inhalable lung medication with the potential to treat COVID-19.

A publicly-traded company, TFF Pharmaceuticals researches and innovates drug products based on its patented Thin Film Freezing, or TFF, technology platform. This freezing process creates dry powder formulations with properties ideal for inhalation and can potentially target SARS-CoV-2, the disease caused by COVID-19, inside the lungs by delivering medication directly to the infection site. TFF has compounds under development that can be used to treat challenging-to-manage lung conditions such as Invasive Pulmonary Aspergillosis, or IPA and COVID-19.

TFF found IRISYS to be a superior partner for the transfer of its technology to IRISYS' labs. IRISYS will be responsible for the initial production and testing of TFF's investigational powder product for inhalation. IRISYS was able to help adapt the process to the needs of the project and to establish a robust manufacturing process suitable for clinical trial materials preparation.

"The most important part of this project is that we are not just helping develop a new formulation, but new technology. With the versatility of this process, any lung therapeutic could potentially be applicable," - JJ Sigler, IRISYS Scientist

The TFF platform was designed to improve the solubility of poorly water-soluble drugs generally, and the technology is particularly useful in generating dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process involves dissolving the drug in a solvent system, and then flash freezing the drug substance. The frozen powder is lyophilized, resulting in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology, allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based on laboratory experiments, the aerodynamic properties of the particles are such that the portion of drug deposited to the deep lung has the potential to reach as high as 75%.

Tags : #IRISYSLLC #TFFPharma #InhalableLungMedication #TreatCOVID-19 #JJSigler #RespiratoryMedicine

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026